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Background. Approximately, one-third of patients with epilepsy are refractory to pharmacological treatment which mandates
extensive medical care and imposes significant economic burden on patients and their societies. This study intends to assess the
impact of the treatment with ketogenic diet (KD) on reducing seizure-related emergency room visits and hospitalizations in children
with refractory epilepsy. Methods. This is a retrospective review of children treated with the KD in one tertiary center. We compared
a 12 months’ period prior to KD with 12 months after the diet was started in regard to the number of emergency department (ED)
visits, hospitalizations, and hospital days as well as their associated charges. Results. 37 patients (57% males) were included. Their
ages at time of KD initiation were (4.0 ± 2.78) years. Twelve months after the KD initiation, the total number of ED visits was
reduced by 36% with a significant decrease of associated charges (𝑝 = 0.038). The number of hospital admissions was reduced by
40% and the number of hospital days was reduced by 39%. The cumulative charges showed net cost savings after 9 months when
compared to the prediet baseline. Conclusion. In children with refractory epilepsy, treatment with the ketogenic diet reduces the
number of ED visits and hospitalizations and their corresponding costs.

1. Introduction
Epilepsy is a common neurological disorder affecting approximately 0.5–1% of the population in the United States. It is
estimated that ∼200,000 new cases per year are diagnosed
in the United States [1]. Most patients with epilepsy achieve
seizure control with antiepileptic medications. However,
about one-third of patients suffer from refractory epilepsy [2].
This imposes a substantial economic burden on the health
care system. In 2000, the burden of epilepsy was estimated to
account for 0.5% of the total burden of diseases in the world
[3]. Begley et al. estimated the annual cost for the 2.3 million
prevalent epilepsy cases in the US in 1995 at $12.5 billion,
with the direct costs being concentrated in patients with
intractable epilepsy [4]. In 2016, this is about $19.5 billion
when correcting the dollar value using CPI inflation calculator. Another study reported that annual direct medical costs
of epilepsy per patient in the United States range from $1,620

to $52,558, depending on disease severity [5]. Drug-resistant
epilepsy was found to be the most expensive category in
a study from Italy, with the major sources of costs being
hospital services followed by anticonvulsants [6].
The ketogenic diet (KD) is a well-established treatment
modality for pharmacologically refractory epilepsy. Indeed,
this diet is considered one of the oldest treatments for epilepsy
in existence. In the 1920s, only phenobarbital and bromides
were available for the treatment of epilepsy. As a result, the
ketogenic diet was created in 1921 at the Mayo Clinic in
Rochester, Minnesota, for children with refractory epilepsy
[7]. Although initially it was very popular, as new anticonvulsants such as phenytoin were introduced, the popularity of the
KD waned. In the 1990s, interest in the KD was reawakened
again in the United States and then around the world [8].
Since then hundreds of publications have been devoted to the
dietary treatment of epilepsy. The efficacy and safety of the
KD in the treatment of epilepsy have been well established
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through many studies [9–12]. The ketogenic diet has been
shown to be particularly effective in pediatric patients with
refractory epilepsy [9, 13–16].
Despite its established efficacy, the data on the effect of the
KD on health care costs and medical resource utilization is
scarce. One case series compared the direct medical costs for
15 children with epilepsy before and after the diet. The authors
reported a drop of the total costs for 6–12-month period from
$352,820 before the diet to $190,659 (including $41,222 for
diet initiation) [17].
We aim to study the effect of the KD treatment on
the number of seizure-related emergency department (ED)
visits, hospital admissions, hospital days, and their associated
charges. This may shed some light on the KD potential
to impact the health care costs of children with refractory
epilepsy.

2. Methods
2.1. Study Design and Sample. This retrospective chart review
included pediatric patients treated with the ketogenic diet
for refractory epilepsy at a tertiary pediatric epilepsy center
between 2009 and 2013. Institutional review board approval
for the study protocol was obtained. The study cohort was
selected based on the following inclusion criteria: (1) epilepsy
was diagnosed and treated by a pediatric neurologist or
epileptologist for ≥12 months prior to KD; (2) patients failed
to respond to conventional pharmacological therapy before
starting the diet; (3) patients were treated with the KD for ≥12
months.
2.2. Outcome Measures. We compared the 12-month period
prior to starting ketogenic diet with the 12 months after the
diet initiation in regard to the (1) number of ED visits; (2)
number of hospital admissions; (3) number of hospital days;
and (4) charges related to ED visits and hospitalizations.
2.3. Statistical Analysis. Descriptive statistics including
means, medians, standard deviations, and proportions with
95% confidence interval were calculated. Paired 𝑡-tests were
used to calculate 𝑝 values. Wilcoxon Signed Rank tests were
used to compare the 12 months before diet to the 12 months
after diet for continuous variables such as total charges. The
incidence rates of ED visits, inpatient visits, and hospital
days were calculated by dividing the number of events by the
patient months of observation. Incidence rate ratios (IRR)
were then used to compare the prediet and postdiet periods
where IRR < 1 indicates a lower incidence of the event in the
postketogenic diet period.

3. Results
3.1. Patient Demographics. 37 patients were included in this
study (Table 1); 21 are males (57%). The average age at onset
of epilepsy is 2.75 years (SD 1.46). The average age at KD
initiation is 4 years (SD 2.78). The average duration of
treatment with KD is 34.5 months (SD 17.89). The number
of anticonvulsants used prior to initiating KD is 3–7 (mean
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Table 1: Patients’ characteristics.
Total number
Gender
Male
Female
Age at epilepsy onset (yr)
Age at KD initiation (yr)
Duration of treatment with KD (mo)
Number of AEDs used prior to KD
Number of AEDs used after KD

37
21 (57%)
16 (43%)
2.75 ± 1.46∗
4.0 ± 2.78∗
34.67 ± 17.89∗
3–7 (mean 4.25)
0–4 (mean 2.32)

∗
These values are the mean ± SD.
KD: ketogenic diet; AEDs: antiepileptic drugs.

4.25), and on the last follow-up visit after the diet 0–4 (mean
2.32) AEDs were used.
3.2. Rates of ED Visits and Hospitalizations. The number of
ED visits recorded for the entire cohort dropped from 66 visits in the 12 months before the diet to 42 visits in the 12 months
after the diet. The incidence rate ratio (IRR) = 0.64 (95% CI
0.43–0.94). When ED visits related directly to seizures were
analyzed separately, we found even more significant decline
with IRR = 0.33 (95% CI 0.17–0.61) (Table 2). Individually, 26
patients (70.3%) experienced a decrease in their numbers of
ED visits after the diet.
The same trend of decline was found in the number of
hospitalizations; the total number of admissions decreased
approximately by 40% (IRR = 0.60, 95% CI 0.39–0.92). The
admissions related directly to epilepsy were decreased even
more (IRR = 0.35, 95% CI 0.19–0.64). The number of hospital
days also decreased at similar rates as summarized in Table 2.
Out of the total cohort, 29 patients (78.4%) had a decrease in
the number of their hospital admissions.
3.3. Charges Related to ED Visits and Hospitalizations. The
average 12-month charges per patient are summarized in
Table 3. The average ED charges decreased significantly in the
post-KD period (𝑝 = 0.0386). Hospitalization charges were
also significantly lower when excluding the charges related to
the diet initiation (0.0052). Figure 1 illustrates the cumulative
cost difference from prediet baseline. The figure shows a trend
of decreasing net charges until negative costs, which indicate
net savings, were achieved 9 months after starting the diet.

4. Discussion
Despite recent advances in the management of epilepsy,
poorly controlled seizures continue to be significant clinical problem affecting approximately 600,000 people in the
United States [18]. Complications due to intractable epilepsy
result in frequent hospitalizations and ED visits. The charges
related to these services are “direct” costs that comprise a
significant portion of the total health care costs imposed on
refractory epilepsy patients. Although the clinical benefits of
the ketogenic diet have been described extensively, information is lacking about its cost-effectiveness.
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Table 2: Rates of ED visits and hospitalization in the pre-KD period versus post-KD period.

ED visits
Seizure-related
Not seizure-related
Hospitalizations
Seizure-related
Not seizure-related
Hospital days
Seizure-related
Not seizure-related
a
b

Incidence rate (IR)a
0.15
0.09
0.06
0.12
0.09
0.03
0.47
0.34
0.13

Before KD
66
40
26
55
40
15
210
152
58

After KD
42
13
29
33
14
19
128
55
73

Incidence rate (IR)a
0.09
0.03
0.07
0.07
0.03
0.04
0.29
0.12
0.16

IRRb
0.64
0.33
1.12
0.60
0.35
1.27
0.61
0.36
1.26

SD (95% CI)
0.197 (0.43–0.94)
0.319 (0.17–0.61)
0.27 (0.66–1.89)
0.22 (0.39–0.92)
0.311 (0.19–0.64)
0.345 (0.64–2.49)
0.112 (0.49–0.76)
0.157 (0.27–0.49)
0.176 (0.89–1.78)

IR = incidence rate: it is the number of events divided by patient-months of observation.
IRR = incidence rate ratio; IRR < 1 indicates a lower incidence of the event in the postketogenic diet period.

Table 3: 12-month charges per patient before and after ketogenic diet.
𝑛 = 37

Pre-KD period

Post-KD period

𝑝 value

Post-KD period
excluding KD admission

𝑝 value

ED charges
Inpatient charges
Total

$2,354 ± 5,935
$33,675 ± 71,145
$36,029 ± 76,179

$1,101 ± 3,586
$30,889 ± 76,173
$31,990 ± 78,488

0.0386
0.4014
0.4812

—
$15,081 ± 70,828
$16,183 ± 73,119

—
0.0052
0.0036

400,000
300,000
200,000
100,000
0
−100,00

−200,00
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Figure 1: Cumulative net charges compared to prediet baseline. Net
savings were achieved at 9 months after starting the diet and were
maintained afterwards.

The diet was reported to have positive impact on the
quality of life of pediatric patients which was attributed
mainly to the decreased number of ED visits and decreased
hospitalizations [19]. In this study we reemphasized the
remarkable effect of the diet on lowering epilepsy-related
ED visits and hospitalizations and subsequently on saving
health care resources. The pre-post study design allowed
us to eliminate intersubject variability by using patients as
their own controls. Because of the unstable natural course
of epilepsy, we elected to compare the immediate 12 months
before diet initiation with the 12 months after initiating
the diet for statistical purposes, knowing that the clinical
effects of the diet appear usually after a variable period of
several weeks after initiation. Even though we did not directly
assess the clinical efficacy of the diet in the study cohort, it
is reasonable to think that the significant reduction in the
number of ED visits and hospitalizations is likely due to
improved seizure control. This is supported by the results that
show particularly remarkable decline in the hospitalizations
and ED visits related to seizures compared to other reasons.

We found a steady decline of the charges related to hospitalizations and ED visits over the course of the 12 months after
the diet initiation. The difference of the ED charges was statistically significant (𝑝 = 0.038). The ketogenic diet initiation
requires 3–7-day admission to the hospital according to our
epilepsy center protocol. We included the charges related to
this hospitalization in the postdiet period. Despite the fact
that our results showed a trend of decreasing net charges
compared to the monthly average of the prediet period, negative costs, which indicate net savings, were achieved 9 months
after starting the diet and were maintained afterwards.
Our analysis did not include other forms of health care
costs like outpatient visit charges, cost of medications, laboratory and radiology tests, and so forth. For this reason, we
acknowledge that our results do not necessarily prove the
cost-effectiveness of the ketogenic diet. However, these results
demonstrate the effectiveness of the diet in decreasing utilization of health care resources. An accurate assessment of
the total cost of epilepsy requires studying both “direct costs”
of medical resources devoted to diagnosing and treating
patients and “indirect costs” from foregone earnings and
reductions in household activities due to epilepsy-related
morbidity and mortality [20]. The results of an ongoing
randomized controlled trial evaluating the cost-effectiveness
of a ketogenic diet are awaited [21]. Such studies are needed
to shed further light on this subject.

5. Conclusion
This study demonstrates that, in children with refractory
epilepsy, treatment with the ketogenic diet reduces the number of emergency department visits and hospitalizations due
to seizure comorbidities, with a corresponding decline in the
costs of these services.
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